Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02952729 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | PHASE1 | COMPLETED | 120 | — | — | Nov 21, 2016 | Jan 28, 2019 | Feb 24, 2021 | 5 | United States |
Evaluate adverse events and use of concomitant medication use after XMT-1522 doses
| Arm | Type | Description |
|---|---|---|
| Dose Escalation and Confirmation | EXPERIMENTAL | XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose. |
| Name | Type | Description |
|---|---|---|
| XMT-1522 | DRUG | one intravenous dose administered in-clinic every 21 days |
Inclusion Criteria: * Able and willing to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease via RECIST * Resolution of all toxic side effects from prior oncology treatments * Adequate organ function as measured by various blood param...